Biomedical subjects

M Zalik

Publications and source records attributed to M Zalik.

3 recordsLinked to original sources

PubMed1999

Sustained complete remission after chemobiohormonal therapy for metastatic melanoma.

The combination of carmustine, cisplatin, dacarbazine, interferon, and low-dose tamoxifen is widely used in treating metastatic melanoma and was originally reported to achieve a 20% complete response rate. Among 29 patients who completed the authors' phase II study with the regimen, five (17%) achieved complete remission, and the median duration of response was 8 months (range, 2-14 months). The aim of the study was to evaluate briefly the value and toxicity of this regimen in treating metastatic malignant melanoma.

Antineoplastic Combined Chemotherapy Protocols↗

PubMed1998

A simple oral cone attachment for the Varian linear accelerator.

Lesions in the oral cavity are often treated with two opposed lateral fields. These include a significant amount of normal healthy tissue whose radiation tolerance is dose-limiting. The tumor dose can be boosted to tumorcidal levels by brachytherapy or by small electron fields directed straight on the lesion. We have developed a simple attachment to the standard electron applicator of the Varian Clinac 1800 that allows irradiation of small electron fields through acrylic tubes-the oral cones. These tubes have been evaluated in terms of depth dose and field profiles for 6, 9, 12, 16, and 20 MeV electrons using film for relative dosimetry. At these small field sizes there are significant changes in output factors, in the depth dose as well as in the effective size of the field, and a thorough dosimetric evaluation is imperative prior to treatment. The attachment can be manufactured locally at low cost. For reasons of patient safety the assembly is collapsible. In clinical practice the cone is directed directly on the tumor. For deep-seated lesions we use a penlight and a mirror for positioning.

Humans↗

PubMedDate not supplied

Fatal neutropenic colitis complicating successful chemotherapy for small cell lung cancer: a case report.

Neutropenic colitis, a severe necrotizing enteropathy, is being recognized with increasing frequency as a life-threatening complication of aggressive chemotherapy mainly for lymphoproliferative and hematologic malignancies. It is often under-recognized clinically, despite its potentially lethal outcome. Both medical and surgical approaches to management are possible. We describe a case of neutropenic colitis involving predominantly the transverse colon in a patient successfully treated for limited-disease small cell lung cancer. This is only the second reported case of neutropenic colitis complicating chemotherapy for small cell lung cancer. A brief review of the diagnosis, clinical features, and management is presented.

Antineoplastic Combined Chemotherapy Protocols↗